โ€”
๋…ผ๋ฌธ
โ€”
Chunks
โ€”
Findings
โ€”
์‹œ๋ฎฌ๋ ˆ์ด์…˜
โ€”
ํƒ€๊ฒŸ
PubMed/OpenAlex โ†’ PDF ํŒŒ์‹ฑ โ†’ Embedding โ†’ PICO+ ์ถ”์ถœ โ†’ RAG ์งˆ์˜์‘๋‹ต โ†’ ๋ถ„์ž ์‹œ๋ฎฌ๋ ˆ์ด์…˜

๐Ÿงฌ ์‹œ๋ฎฌ๋ ˆ์ด์…˜ ๊ฒฐ๊ณผ

#ํƒ€๊ฒŸ๋ฆฌ๊ฐ„๋“œ์œ ํ˜•์—”์ง„์ ์ˆ˜์‹ ๋ขฐ๋„
1EGFRcetuximabํ•ญ์ฒด ์ธํ„ฐํŽ˜์ด์ŠคBiopython 25 contacts, ~200 ร…ยฒEXPERIMENTAL
2EGFRerlotinib์†Œ๋ถ„์ž ๋„ํ‚นBoltz-2 confidence 0.788, iptm 0.981HIGH
3PD-1pembrolizumabํ•ญ์ฒด ์ธํ„ฐํŽ˜์ด์ŠคBiopython 52 contacts, ~340 ร…ยฒEXPERIMENTAL
4PD-1nivolumabํ•ญ์ฒด ์ธํ„ฐํŽ˜์ด์ŠคBiopython 32 contacts, ~220 ร…ยฒEXPERIMENTAL
5EGFRerlotinib์†Œ๋ถ„์ž ๋„ํ‚นVina -7.605 kcal/molMEDIUM
6HPV E6p53๋ณตํ•ฉ์ฒด ์˜ˆ์ธกBoltz-2 confidence 0.366EXPLORATORY
7HPV E7Rb๋ณตํ•ฉ์ฒด ์˜ˆ์ธกBoltz-2 confidence 0.395EXPLORATORY
8PI3Kฮฑalpelisib์†Œ๋ถ„์ž ๋„ํ‚นBoltz-2 confidence 0.311EXPLORATORY
9mTOReverolimus์†Œ๋ถ„์ž ๋„ํ‚นโ€” โ€”๋Œ€๊ธฐ ์ค‘
10PD-L1atezolizumabํ•ญ์ฒด ๋ณตํ•ฉ์ฒดBoltz-2 ๋ณตํ•ฉ์ฒด ์˜ˆ์ธก ์™„๋ฃŒMEDIUM
11EGFRnimotuzumabํ•ญ์ฒด ๋ณตํ•ฉ์ฒดBoltz-2 ๋ณตํ•ฉ์ฒด ์˜ˆ์ธก ์™„๋ฃŒMEDIUM
12KRT6Aโ€”๊ตฌ์กฐ ์˜ˆ์ธกBoltz-2 ํ•ญPD-1 ๋‚ด์„ฑ ๋ฐ”์ด์˜ค๋งˆ์ปคMEDIUM
13PD-L1โ€”๊ตฌ์กฐ ์˜ˆ์ธกBoltz-2 ๊ตฌ์กฐ ์˜ˆ์ธก ์™„๋ฃŒMEDIUM
14WBP5pazopanib์†Œ๋ถ„์ž ๋„ํ‚นBoltz-2 confidence 0.499, iptm 0.478EXPLORATORY

๐Ÿ“š ๋…ผ๋ฌธ ์ปค๋ฒ„๋ฆฌ์ง€

๋ถ„์•ผ๋…ผ๋ฌธ ์ˆ˜์ฃผ์š” ํ‚ค์›Œ๋“œ
์•ˆ๊ณผ~900trifocal IOL, glaucoma, cataract, MIGS, OCT
๋‘๊ฒฝ๋ถ€ (HNSCC)~1,500cetuximab, pembrolizumab, HPV, EGFR, PD-L1
ํŽฉํƒ€์ด๋“œ/์žฅ์ˆ˜~2,200BPC-157, SS-31, MOTS-c, semaglutide, NAD+
PubMed MeSH Baseline~15,000+MeSH ํ•„ํ„ฐ๋ง (60๊ฐœ MeSH term)

๐Ÿงฌ ์‹œ๋ฎฌ๋ ˆ์ด์…˜ ์—”์ง„

์—”์ง„์šฉ๋„์‹คํ–‰๋น„์šฉ
Boltz-2AI ๊ตฌ์กฐ ์˜ˆ์ธก + ๊ฒฐํ•ฉModal GPU (ํด๋ผ์šฐ๋“œ)~$0.02/๊ฑด
AutoDock Vina์ „ํ†ต physics-based ๋„ํ‚น๋กœ์ปฌ (Ryan-home)๋ฌด๋ฃŒ
Biopython์ธํ„ฐํŽ˜์ด์Šค ๋ถ„์„๋กœ์ปฌ๋ฌด๋ฃŒ